In RESIST, enfuvirtide co-administered with ritonavir-boosted tipranavir was associated with higher plasma tipranavir concentrations, which seldom rose above those associated with an increased risk of grade 3/4 transaminase elevations. Transaminase elevation rates (6.5%) and clinical hepatic event rates (5.9 events/100 person exposure years) were lower in the tipranavir/ritonavir with enfuvirtide group than in the tipranavir/ritonavir without enfuvirtide group. Observed increases in plasma tipranavir concentrations thus had no apparent effect on the risk of hepatotoxicity.
|Titolo:||Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST|
|Parole Chiave:||Randomized Controlled Trials as Topic; HIV Protease Inhibitors; Liver Diseases; Pyrones; Anti-HIV Agents; Saquinavir; Humans; Pyridines; HIV-1; Alanine Transaminase; Viral Load; Drug Therapy, Combination; HIV Envelope Protein gp41; Drug-Induced Liver Injury; Peptide Fragments; Lopinavir; Ritonavir; HIV Infections; Pyrimidinones; Treatment Outcome; HIV Fusion Inhibitors|
|Settore Scientifico Disciplinare:||Settore MED/17 - Malattie Infettive|
|Data di pubblicazione:||12-set-2007|
|Digital Object Identifier (DOI):||10.1097/QAD.0b013e3282ef8600|
|Appare nelle tipologie:||01 - Articolo su periodico|